Alvotech (ALVO)

Market Cap	3.59B
Revenue (ttm)	393.92M
Net Income (ttm)	-441.45M
Shares Out	301.64M
EPS (ttm)	-1.74
PE Ratio	n/a
Forward PE	92.33
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,188,213
Open	11.99
Previous Close	12.11
Day's Range	11.70 - 12.00
52-Week Range	9.15 - 18.00
Beta	-0.15
Analysts	Buy
Price Target	18.00 (+51.13%)
Earnings Date	Nov 13, 2024

About ALVO

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company’s lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory cond...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2013
• Employees: 999
• Stock Exchange: NASDAQ
• Ticker Symbol: ALVO
• Website: https://www.alvotech.com

Financial Performance

In 2023, Alvotech's revenue was $93.38 million, an increase of 9.84% compared to the previous year's $85.02 million. Losses were -$551.73 million, 7.43% more than in 2022.

Analyst Forecast

According to one analyst, the rating for ALVO stock is "Buy" and the 12-month stock price forecast is $18.0.

Price Target

$18.0

(51.13% upside)

Analyst Consensus: Buy